Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study tests the hypothesis that systemic and renal nitric oxide synthesis is changed in essential hypertension by investigating the effects of a non selective nitric oxide inhibitor on renal hemodynamics and sodium excretion in patients with essential hypertension. The results are compared with a group of healthy subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:

1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
2. renal sodium excretion
3. lithium clearance and fractional lithium excretion
4. plasma levels of vasoactive hormones
5. blood pressure and heart rate

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hypertension nitric oxide renal hemodynamics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ng-monomethyl-L-arginine (drug)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Essential hypertension (blood pressure \> 140/90) with no signs of secondary hypertension
* P-creatinine \< 200 µmol/L

Exclusion Criteria

* Anamnestic or clinical signs of heart disease, renal disease, liver disease, neoplastic disease, anemia or cerebro-vascular insult
* Medication except antihypertensives
* Drug or alcohol abuse
* Pregnancy

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jesper N Bech, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

Erling B Pedersen, Professor

Role: STUDY_CHAIR

Holstebro Hospital, 7500 Holstebro, Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MED.RES.HOS.1995.01.JNB

Identifier Type: -

Identifier Source: org_study_id